Children born small for gestational age (SGA) exhibited impaired glucose-insulin metabolism, similar to children with obesity, which worsened under growth hormone therapy. In contrast, children with ...

Novo Nordisk’s Sogroya is now approved for children aged 2.5 or older with idiopathic short stature, small for gestational age, and Noonan Syndrome.

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya (R) (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...

Battles are emerging between tech companies and governments that are trying to limit the harm to children and adolescents ...

The FDA has approved three new pediatric indications for somapacitan-beco, a once-weekly, long-acting growth hormone injection, according to a press release issued by Novo Nordisk.Somapacitan-beco ...

FDA expands Sogroya approval for pediatric patients with Noonan syndrome, idiopathic short stature, and those born small for gestational age.

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya® (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...

Here are the common bedtime habits that may harm your child’s sleep, growth and brain development and know expert tips to ...

A kid’s bedtime routine is key for their development, mood, and overall well-being. Some bedtime habits can interfere with sleep and impact growth. Child behaviour experts say that putting an end to c ...

Safi was born at the Rosie Hospital, Cambridge in December 2024. She was one of the first babies participating in the ...

Novo Nordisk received approval from the Food and Drug Administration for three new indications of Sogroya, a growth hormone.

Novo Nordisk A/S (NYSE:NVO) is one of the best cheap stocks under $50 to buy right now. Novo Nordisk A/S (NYSE:NVO) announced ...